APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotheraphy-induced Nausea and Vomitting Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chemotheraphy-induced Nausea and Vomitting Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025195 pages

Choose your research edition.

Industry ResearchChemotheraphy-induced Nausea and Vomitting Treatment Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Chemotheraphy-induced Nausea and Vomitting Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chemotheraphy-induced Nausea and Vomitting Treatment include Eisai, Merck & Co, GlaxoSmithKline, Tesaro, Orchid Healthcare, OPKO Health, Mylan Pharmaceuticals, Mundipharma and Heron Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Chemotheraphy-induced Nausea and Vomitting Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chemotheraphy-induced Nausea and Vomitting Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chemotheraphy-induced Nausea and Vomitting Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Chemotheraphy-induced Nausea and Vomitting Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Company

Eisai

Merck & Co

GlaxoSmithKline

Tesaro

Orchid Healthcare

OPKO Health

Mylan Pharmaceuticals

Mundipharma

Heron Therapeutics

Helsinn

F.Hoffmann La Roche

Especificos Stendhal

Baxter Healthcare

Barr Laboratories

Aphios

Acacia Pharma

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Type

5-HT3 Inhibitors

NK1 Inhibitors

Others

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Application

Delayed Nausea and Vomitting Treatment

Acute Nausea and Vomitting Treatment

Anticipatory Nausea and Vomitting Treatment

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotheraphy-induced Nausea and Vomitting Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotheraphy-induced Nausea and Vomitting Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotheraphy-induced Nausea and Vomitting Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Chemotheraphy-induced Nausea and Vomitting Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chemotheraphy-induced Nausea and Vomitting Treatment industry.

Chapter 3: Detailed analysis of Chemotheraphy-induced Nausea and Vomitting Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotheraphy-induced Nausea and Vomitting Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of 5-HT3 Inhibitors Table 3. Key Players of NK1 Inhibitors Table 4. Key Players of Others Table 4. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Delayed Nausea and Vomitting Treatment Table 6. Key Players of Acute Nausea and Vomitting Treatment Table 7. Key Players of Anticipatory Nausea and Vomitting Treatment Table 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2021-2026) Table 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region (2027-2032) Table 13. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends Table 14. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Drivers Table 15. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Opportunities and Challenges Table 16. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Restraints Table 17. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Company (2021-2026) Table 19. Global Chemotheraphy-induced Nausea and Vomitting Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Chemotheraphy-induced Nausea and Vomitting Treatment Key Company Head Office and Area Served Table 21. Global Chemotheraphy-induced Nausea and Vomitting Treatment Company, Product Type & Application Table 22. Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Chemotheraphy-induced Nausea and Vomitting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Application (2027-2032) Table 35. Eisai Company Information Table 36. Eisai Business Overview Table 37. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 39. Eisai Recent Development Table 40. Merck & Co Company Information Table 41. Merck & Co Business Overview Table 42. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 44. Merck & Co Recent Development Table 45. GlaxoSmithKline Company Information Table 46. GlaxoSmithKline Business Overview Table 47. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 49. GlaxoSmithKline Recent Development Table 50. Tesaro Company Information Table 51. Tesaro Business Overview Table 52. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 54. Tesaro Recent Development Table 55. Orchid Healthcare Company Information Table 56. Orchid Healthcare Business Overview Table 57. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 59. Orchid Healthcare Recent Development Table 60. OPKO Health Company Information Table 61. OPKO Health Business Overview Table 62. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 64. OPKO Health Recent Development Table 65. Mylan Pharmaceuticals Company Information Table 66. Mylan Pharmaceuticals Business Overview Table 67. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 69. Mylan Pharmaceuticals Recent Development Table 70. Mundipharma Company Information Table 71. Mundipharma Business Overview Table 72. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 74. Mundipharma Recent Development Table 75. Heron Therapeutics Company Information Table 76. Heron Therapeutics Business Overview Table 77. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 79. Heron Therapeutics Recent Development Table 80. Helsinn Company Information Table 81. Helsinn Business Overview Table 82. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 84. Helsinn Recent Development Table 85. F.Hoffmann La Roche Company Information Table 86. F.Hoffmann La Roche Business Overview Table 87. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 89. F.Hoffmann La Roche Recent Development Table 90. Especificos Stendhal Company Information Table 91. Especificos Stendhal Business Overview Table 92. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 94. Especificos Stendhal Recent Development Table 95. Baxter Healthcare Company Information Table 96. Baxter Healthcare Business Overview Table 97. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 99. Baxter Healthcare Recent Development Table 100. Barr Laboratories Company Information Table 101. Barr Laboratories Business Overview Table 102. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 104. Barr Laboratories Recent Development Table 105. Aphios Company Information Table 106. Aphios Business Overview Table 107. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 108. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 109. Aphios Recent Development Table 110. Acacia Pharma Company Information Table 111. Acacia Pharma Business Overview Table 112. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 113. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 114. Acacia Pharma Recent Development Table 115. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026) & (US$ Million) Table 116. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032) & (US$ Million) Table 117. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026) & (US$ Million) Table 118. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032) & (US$ Million) Table 119. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) Table 121. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032) Table 122. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026) & (US$ Million) Table 123. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032) & (US$ Million) Table 124. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026) & (US$ Million) Table 125. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032) & (US$ Million) Table 126. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) Table 128. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032) Table 129. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026) & (US$ Million) Table 130. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032) & (US$ Million) Table 131. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026) & (US$ Million) Table 132. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032) & (US$ Million) Table 133. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026) & (US$ Million) Table 134. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032) & (US$ Million) Table 135. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026) & (US$ Million) Table 136. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032) & (US$ Million) Table 137. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) Table 139. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032) Table 140. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026) & (US$ Million) Table 141. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032) & (US$ Million) Table 142. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026) & (US$ Million) Table 143. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032) & (US$ Million) Table 144. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026) Table 146. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032) Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Chemotheraphy-induced Nausea and Vomitting Treatment Product Image Figure 2. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type: 2025 VS 2032 Figure 4. 5-HT3 Inhibitors Image Figure 5. NK1 Inhibitors Image Figure 6. Others Image Figure 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2025 VS 2032 Figure 9. Delayed Nausea and Vomitting Treatment Image Figure 10. Acute Nausea and Vomitting Treatment Image Figure 11. Anticipatory Nausea and Vomitting Treatment Image Figure 12. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 14. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Chemotheraphy-induced Nausea and Vomitting Treatment Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 24. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032) Figure 25. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032) Figure 26. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 27. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 28. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 30. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 31. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032) Figure 32. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032) Figure 33. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 34. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 35. France Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 37. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 38. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 40. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 41. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032) Figure 42. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032) Figure 43. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 44. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032) Figure 45. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032) Figure 46. Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 47. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 51. India Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 52. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032) Figure 57. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 62. UAE Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 64. Chile Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • 5-HT3 Inhibitors
  • NK1 Inhibitors
  • Others
Applications
  • Delayed Nausea and Vomitting Treatment
  • Acute Nausea and Vomitting Treatment
  • Anticipatory Nausea and Vomitting Treatment
Companies covered
  • Eisai
  • Merck & Co
  • GlaxoSmithKline
  • Tesaro
  • Orchid Healthcare
  • OPKO Health
  • Mylan Pharmaceuticals
  • Mundipharma
  • Heron Therapeutics
  • Helsinn
  • F.Hoffmann La Roche
  • Especificos Stendhal
  • Baxter Healthcare
  • Barr Laboratories
  • Aphios
  • Acacia Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 5-HT3 Inhibitors
  5. 1.2.3 NK1 Inhibitors
  6. 1.2.4 Others
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Delayed Nausea and Vomitting Treatment
  10. 1.3.3 Acute Nausea and Vomitting Treatment
  11. 1.3.4 Anticipatory Nausea and Vomitting Treatment
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Region
  14. 1.5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2021-2026)
  16. 1.5.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
  1. 2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
  2. 2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Drivers
  3. 2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Opportunities and Challenges
  4. 2.4 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Company (2021-2026)
  2. 3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Key Company Head office and Area Served
  4. 3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company, Product Type & Application
  5. 3.5 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Chemotheraphy-induced Nausea and Vomitting Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Chemotheraphy-induced Nausea and Vomitting Treatment Tier 1, Tier 2, and Tier 3
4 Chemotheraphy-induced Nausea and Vomitting Treatment Market by Type
  1. 4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2032)
  3. 4.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Type (2021-2032)
5 Chemotheraphy-induced Nausea and Vomitting Treatment Market by Application
  1. 5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2032)
  3. 5.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Eisai
  2. 6.1.1 Eisai Company Information
  3. 6.1.2 Eisai Business Overview
  4. 6.1.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  6. 6.1.5 Eisai Recent Developments
  7. 6.2 Merck & Co
  8. 6.2.1 Merck & Co Company Information
  9. 6.2.2 Merck & Co Business Overview
  10. 6.2.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  12. 6.2.5 Merck & Co Recent Developments
  13. 6.3 GlaxoSmithKline
  14. 6.3.1 GlaxoSmithKline Company Information
  15. 6.3.2 GlaxoSmithKline Business Overview
  16. 6.3.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  18. 6.3.5 GlaxoSmithKline Recent Developments
  19. 6.4 Tesaro
  20. 6.4.1 Tesaro Company Information
  21. 6.4.2 Tesaro Business Overview
  22. 6.4.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  24. 6.4.5 Tesaro Recent Developments
  25. 6.5 Orchid Healthcare
  26. 6.5.1 Orchid Healthcare Company Information
  27. 6.5.2 Orchid Healthcare Business Overview
  28. 6.5.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  30. 6.5.5 Orchid Healthcare Recent Developments
  31. 6.6 OPKO Health
  32. 6.6.1 OPKO Health Company Information
  33. 6.6.2 OPKO Health Business Overview
  34. 6.6.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  36. 6.6.5 OPKO Health Recent Developments
  37. 6.7 Mylan Pharmaceuticals
  38. 6.7.1 Mylan Pharmaceuticals Company Information
  39. 6.7.2 Mylan Pharmaceuticals Business Overview
  40. 6.7.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  42. 6.7.5 Mylan Pharmaceuticals Recent Developments
  43. 6.8 Mundipharma
  44. 6.8.1 Mundipharma Company Information
  45. 6.8.2 Mundipharma Business Overview
  46. 6.8.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  48. 6.8.5 Mundipharma Recent Developments
  49. 6.9 Heron Therapeutics
  50. 6.9.1 Heron Therapeutics Company Information
  51. 6.9.2 Heron Therapeutics Business Overview
  52. 6.9.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  54. 6.9.5 Heron Therapeutics Recent Developments
  55. 6.10 Helsinn
  56. 6.10.1 Helsinn Company Information
  57. 6.10.2 Helsinn Business Overview
  58. 6.10.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  60. 6.10.5 Helsinn Recent Developments
  61. 6.11 F.Hoffmann La Roche
  62. 6.11.1 F.Hoffmann La Roche Company Information
  63. 6.11.2 F.Hoffmann La Roche Business Overview
  64. 6.11.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  66. 6.11.5 F.Hoffmann La Roche Recent Developments
  67. 6.12 Especificos Stendhal
  68. 6.12.1 Especificos Stendhal Company Information
  69. 6.12.2 Especificos Stendhal Business Overview
  70. 6.12.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  72. 6.12.5 Especificos Stendhal Recent Developments
  73. 6.13 Baxter Healthcare
  74. 6.13.1 Baxter Healthcare Company Information
  75. 6.13.2 Baxter Healthcare Business Overview
  76. 6.13.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  78. 6.13.5 Baxter Healthcare Recent Developments
  79. 6.14 Barr Laboratories
  80. 6.14.1 Barr Laboratories Company Information
  81. 6.14.2 Barr Laboratories Business Overview
  82. 6.14.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  84. 6.14.5 Barr Laboratories Recent Developments
  85. 6.15 Aphios
  86. 6.15.1 Aphios Company Information
  87. 6.15.2 Aphios Business Overview
  88. 6.15.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  90. 6.15.5 Aphios Recent Developments
  91. 6.16 Acacia Pharma
  92. 6.16.1 Acacia Pharma Company Information
  93. 6.16.2 Acacia Pharma Business Overview
  94. 6.16.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  96. 6.16.5 Acacia Pharma Recent Developments
7 North America
  1. 7.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
  2. 7.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
  3. 7.2.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032)
  6. 7.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
  7. 7.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032)
  10. 7.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
  11. 7.4.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
  2. 8.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
  3. 8.2.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
  7. 8.3.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
  11. 8.4.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
  2. 9.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
  3. 9.2.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032)
  6. 9.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
  7. 9.3.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
  2. 10.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
  3. 10.2.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
  7. 10.3.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
  11. 10.4.1 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst